Pertussis toxin neutralizing antibody response after an acellular booster vaccination in Dutch and Finnish participants of different age groups

References

• de Melker HE, Conyn-van Spaendonck MA, Rumke HC, et al. Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. Emerg Infect Dis. 1997;3(2):175–178.
   PubMed Web of Science ®Google Scholar
• de Greeff SC, de Melker HE, van Gageldonk PG, et al. Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS One. 2010;5(12):e14183.
   PubMed Web of Science ®Google Scholar
• Versteegen P, Berbers G, Smits G, et al. More than 10 years after introduction of an acellular pertussis vaccine in infancy: a cross-sectional serosurvey of pertussis in the Netherlands. The Lancet Regional Health - Europe. 2021;10:100196.
   PubMedGoogle Scholar
• Elomaa A, He Q, Minh NN, et al. Pertussis before and after the introduction of acellular pertussis vaccines in Finland. Vaccine. 2009;27(40):5443–5449.
   PubMed Web of Science ®Google Scholar
• Disease data from ECDC surveillance Atlas for pertussis. (2019). [cited 2021 Sep 7]. Available from: http://ecdc.europa.eu/en/pertussis/surveillance-and-disease-data/atlas.
   Google Scholar
• Le T, Cherry JD, Chang SJ, et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis. 2004;190(3):535–544.
   PubMed Web of Science ®Google Scholar
• Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012;367(11):1012–1019.
   PubMed Web of Science ®Google Scholar
• Sheridan SL, Ware RS, Grimwood K, et al. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA. 2012;308(5):454–456.
   PubMed Web of Science ®Google Scholar
• Hendrikx LH, Felderhof MK, Ozturk K, et al. Enhanced memory B-cell immune responses after a second acellular pertussis booster vaccination in children 9 years of age. Vaccine. 2011;30(1):51–58.
   PubMed Web of Science ®Google Scholar
• Hendrikx LH, Schure RM, Ozturk K, et al. Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children. Vaccine. 2011;29(40):6874–6880.
   PubMed Web of Science ®Google Scholar
• Hallander HO, Gustafsson L, Ljungman M, et al. Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine. 2005;23(46-47):5359–5364.
   PubMed Web of Science ®Google Scholar
• Riffelmann M, Littmann M, Hulsse C, et al. Antibody decay after immunisation of health-care workers with an acellular pertussis vaccine. Eur J Clin Microbiol Infect Dis. 2009;28(3):275–279.
   PubMed Web of Science ®Google Scholar
• Cherry JD, Gornbein J, Heininger U, et al. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 1998;16(20):1901–1906.
   PubMed Web of Science ®Google Scholar
• Storsaeter J, Hallander HO, Gustafsson L, et al. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 1998;16(20):1907–1916.
   PubMed Web of Science ®Google Scholar
• Hewlett EL, Halperin SA. Serological correlates of immunity to Bordetella pertussis. Vaccine. 1998;16(20):1899–1900.
   PubMed Web of Science ®Google Scholar
• Mills KH. Immunity to Bordetella pertussis. Microbes Infect. 2001;3(8):655–677.
   PubMed Web of Science ®Google Scholar
• Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A. 2014;111(2):787–792.
   PubMed Web of Science ®Google Scholar
• Hewlett EL, Sauer KT, Myers GA, et al. Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin. Infect Immun. 1983;40(3):1198–1203.
   PubMed Web of Science ®Google Scholar
• Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden–protective efficacy and adverse events. Lancet. 1988;1(8592):955–960.
   PubMed Web of Science ®Google Scholar
• Blennow M, Granstrom M. Long term serologic follow-up after pertussis immunization. Pediatr Infect Dis J. 1990;9(1):21–26.
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Francis AB, Marsocci SM, et al. Safety and immunogenicity of an acellular pertussis vaccine booster in 15- to 20-month-old children previously immunized with acellular or whole-cell pertussis vaccine as infants. Pediatrics. 1993;91(4):756–760.
   PubMed Web of Science ®Google Scholar
• Edwards KM, Meade BD, Decker MD, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics. 1995;96(3Pt2):548–557.
   PubMedGoogle Scholar
• Meade BD, Lynn F, Reed GF, et al. Relationships between functional assays and enzyme immunoassays as measurements of responses to acellular and whole-cell pertussis vaccines. Pediatrics. 1995;96(3Pt2):595–600.
   PubMedGoogle Scholar
• Barkoff A, Knuutila A, Mertsola J, et al. Evaluation of Anti-PT Antibody Response after Pertussis Vaccination and Infection: The Importance of Both Quantity and Quality. Toxins (Basel). 2021;13(8)508.
   PubMed Web of Science ®Google Scholar
• Trollfors B, Krantz I, Sigurs N, et al. Toxin-neutralizing antibodies in patients with pertussis, as determined by an assay using Chinese hamster ovary cells. J Infect Dis. 1988;158(5):991–995.
   PubMed Web of Science ®Google Scholar
• Carlsson RM, Claesson BA, Fagerlund E, et al. Antibody persistence in five-year-old children who received a pentavalent combination vaccine in infancy. Pediatr Infect Dis J. 2002;21(6):535–541.
   PubMed Web of Science ®Google Scholar
• Dalby T, Sørensen C, Petersen JW, et al. Pertussis serology: assessment of IgG anti-PT ELISA for replacement of the CHO cell assay. APMIS. 2010;118(12):968–972.
   PubMed Web of Science ®Google Scholar
• Isacson J, Trollfors B, Lagergrd T, et al. Comparison of a toxin neutralization assay and ELISA for determination of pertussis toxin antibodies. Serodiagnosis Immunotherapy Infectious Dis. 1997;8(3):163–167.
   Google Scholar
• Storsaeter J, Hallander H, Farrington CP, et al. Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine. 1990;8(5):457–461.
   PubMed Web of Science ®Google Scholar
• Versteegen P, Valente Pinto M, Barkoff AM, et al. Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom. EBioMedicine. 2021;65:103247.
   PubMed Web of Science ®Google Scholar
• van Gageldonk PG, van Schaijk FG, van der Klis FR, et al. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods. 2008;335(1-2):79–89.
   PubMed Web of Science ®Google Scholar
• Gillenius P, Jäätmaa E, Askelöf P, et al. The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells. J Biol Stand. 1985;13(1):61–66.
   PubMedGoogle Scholar
• Zhang Y, Li Y, Chen Z, et al. Determination of serum neutralizing antibodies reveals important difference in quality of antibodies against pertussis toxin in children after infection. Vaccine. 2021;39(13):1826–1830.
   PubMed Web of Science ®Google Scholar
• Moriuchi T, Otsuka N, Hiramatsu Y, et al. A high seroprevalence of antibodies to pertussis toxin among Japanese adults: Qualitative and quantitative analyses. PLoS One. 2017;12(7):e0181181.
   PubMed Web of Science ®Google Scholar
• Barkoff AM, Grondahl-Yli-Hannuksela K, He Q. Seroprevalence studies of pertussis: what have we learned from different immunized populations. Pathog Dis. 2015;73(7):ftv050.
   PubMed Web of Science ®Google Scholar
• Berbers G, van Gageldonk P, Kassteele JV, et al. Circulation of pertussis and poor protection against diphtheria among middle-aged adults in 18 European countries. Nat Commun. 2021;12(1):1–13.
   PubMed Web of Science ®Google Scholar
• Minh NN T, He Q, Ramalho A, et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics. 1999;104(6):e70.
   PubMed Web of Science ®Google Scholar
• Carlsson RM, Claesson BA, Selstam U, et al. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J. 1998;17(11):1026–1033.
   PubMed Web of Science ®Google Scholar
• Xing D, von Konig W, Newland P CH, et al. Characterization of reference materials for human antiserum to pertussis antigens by an international collaborative study. Clin Vaccine Immunol. 2009;16(3):303–311.
   PubMedGoogle Scholar
• Granstrom M, Thoren M, Blennow M, et al. Acellular pertussis vaccine in adults: adverse reactions and immune response. Eur J Clin Microbiol. 1987;6(1):18–21.
   PubMedGoogle Scholar